Table 2 Liver outcome in severe and non-severe COVID-19 patients
Sample size | Number of patients with abnormal liver function | Patients with pre-existing liver conditions | Positive liver histopathology findings | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Total patients | Non-severe COVID | Severe COVID | Total patients | Non-severe COVID | Severe COVID | Total | Non-severe | Severe | ||
Cai et al. [12] | 417 | 318 (76.3%) | 233 (71.5%) | 85 (93.4%) | 21 (5%) | nd | nd | nd | ||
Chen et al. [13] | 274 | 84 (31) | 25 (16) | 59 (52%) | nd | nd | ||||
Guan et al. [14] | 1099 | 168/77 (22.2%) | 112/615 (18.2%) | 56/142 (39.4%) | 23 (2.1) | 22 (2.4%) | 1 (0.6) | nd | ||
Huang et al. [15] | 41 | 15 (31%) | 7/25 (25%) | 8/13 (62%) | 1 (2.0%) | 1 (4%) | 0 | nd | ||
Lagana et al. [16] | 40 | 40 (100%) | 40 (100%) | 2/16 (13%) | 2/16 (13%) | 40 100% | 40 100% | |||
Shi et al. [17] | 81 | 43 (53%) | 4 (27%) | 13 (62%) | 7 (9%) | 0 | 2 (10%) | nd | ||
Sonzogni et al. [18] | 48 | (40/41) 97.6% | (40/4) 97.6% | nd | 48 100% | 48 100% | ||||
Tian et al. [19] | 4 | 1 | 0 | 1 | 1 | 0 | 1 | 1 25% | 0 | 1 100% |
Wander et al. [20] | 1 | 1 | 1 | nd | nd | |||||
Xie et al. [21] | 79 | 35% | 13% | 77.80% | nd | nd | ||||
Xu et al. [22] | 1 | 1 | 0 | 1 | nd | 1 100% | 0 | 1 100% | ||
Xu et al. [23] | 62 | 10 (16%) | 5 (17%) | 5(15%) | 7 (11) | 3 (10%) | 4 (12%) | nd | ||
Yang et al. [24] | 52 | 15 (29%) | 28% | 30% | nd | nd | nd | nd | ||
Zhang et al. [25] | 645 | 81 | 6 (8.3%) | 75 (13.1%) | 25 | 2 (2.8%) | 23 (4.0%) | nd | ||
Zhao et al. [26] | 91 | 18 (19.8%) | 5/61 (16.4%) | 8/30 (26.7%) | nd | nd | ||||